Applying the discovery of the Philadelphia chromosome.

  title={Applying the discovery of the Philadelphia chromosome.},
  author={Daniel W. Sherbenou and Brian J. Druker},
  journal={The Journal of clinical investigation},
  volume={117 8},
The identification of the Philadelphia chromosome in cells from individuals with chronic myelogenous leukemia (CML) led to the recognition that the BCR-ABL tyrosine kinase causes CML. This in turn led to the development of imatinib mesylate, a clinically successful inhibitor of the BCR-ABL kinase. Incorporating the use of markers of BCR-ABL kinase inhibition into clinical trials led to the realization that imatinib-resistant kinase domain mutations are the major cause of relapse during imatinib… CONTINUE READING